Commentary|Videos|September 2, 2025
Adding Blinatumomab to the CALGB 10403 Regimen in B-Cell Precursor ALL in MRD-Negative Remission
Author(s)Ibrahim Aldoss, MD, Shira Dinner, MD
Shira Dinner, MD, and Ibrahim Aldoss, MD, discuss the addition of blinatumomab to the CALGB 10403 regimen in MRD-negative acute lymphoblastic leukemia.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
The FDA set a PDUFA target action date of March 31, 2027, for tabelecleucel in relapsed or refractory EBV-positive posttransplant lymphoproliferative disease.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Advertisement
Advertisement
Trending on OncLive
1
Polls Reveal Top Picks for Lung Cancer Abstracts of Interest at ESMO 2026
2
Poll Results Highlight Gynecologic Cancer Abstracts of Interest at ESMO 2026
3
HER2+ mCRC Treatment Sequencing Favors Tucatinib Plus Trastuzumab Before T-DXd
4
Adjuvant Giredestrant Preserves QOL With Sustained Tolerability in ER+, HER2– Early Breast Cancer
5